Abstract. The signal regulatory protein (SIRP) α1 is a cell surface receptor expressed predominantly in monocytes, granulocytes, dendritic cells, as well as hematopoietic stem cells. In contrast, SIRPα1 expression is significantly reduced in the majority of myeloid malignancies. SIRPα1 is a negative regulator of signaling and its reduced expression is considered to play a role in the pathogenesis of these diseases through aberrant signaling. To identify SIRPα1 downstream target genes, we established SIRP α1-knockdown chronic myeloid leukemia K562 (K562SIRPα1Kd) cells expressing reduced levels of SIRPα1 by stably transfecting SIRPα1 siRNAs. Microarray analysis demonstrated that several genes, including β-catenin, were significantly induced in K562SIRPα1Kd cells. Realtime PCR and Western blot analyses, confirmed the induction of this gene. Phosphorylation of Ser9 of glycogen synthesis kinase (GSK) -3β, results in the inactivation of GSK-3β, leading to the induction of β-catenin. We found significant phosphorylation of extracellular signal-regulated kinase (ERK), Akt, as well as of GSK-3β-Ser9, which may play a role in the up-regulation of β-catenin in K562SIRPα1Kd cells. To our knowledge, this is a first report demonstrating the relationships between SIRPα1 and β-catenin in leukemia cells.
Introduction
The signal regulatory proteins (SIRPs) comprise a family of cell surface receptors that regulate signal transduction through tyrosine kinase receptors by interacting with Src homology 2 domain-containing protein tyrosine phosphatases (SHP) -1 and SHP-2 (1). SIRPs are also termed Src homology 2 domain-containing phosphatase substrate-1 (SHPS-1), brain immunoglobulin-like molecule with a tyrosine-based activation motif (BIT), p84, and macrophage fusion receptor (MFR). SIRPs are transmembrane glycoproteins consisting of a large extracellular region with 3 immunoglobulin-like domains, a single hydrophobic transmembrane region, and a cytoplasmic tail containing 2 immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (1) . In humans, there are at least 15 members designated as SIRPs. They consist of two subtypes distinguished by the presence or absence of a cytoplasmic domain containing ITIMs. SIRPα1 is the most characterized member of the human SIRP family. Its overexpression leads to a reduced responsiveness to tyrosine kinase ligands, such as epidermal growth factor (EGF), platelet-derived growth factor (PdGF) and insulin (1) . Therefore, SIRPα1 is considered as a negative regulator of signaling.
SIRPα1 is expressed predominantly in monocytes, granulocytes, dendritic cells, and their precursors, as well as in bone marrow hematopoietic stem cells (2) . In contrast, SIRPα1 expression is absent or significantly reduced in the majority of myeloid blasts from patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (cML) (2) . The data suggest that the down-regulation of SIRPα1 plays a role in the aberrant signal transduction, contributing to the pathogenesis of hematological malignancies.
In the present study, we first cloned cell lines expressing reduced levels of SIRPα1 by stable transfection of SIRPα1 short inhibitory RNAs (siRNAs) and tried to identify the target genes regulated by SIRPα1. By performing microarray analysis between SIRPα1-knockdown cells and parental cells, we found that β-catenin was significantly induced in SIRPα1-knockdown cells. Furthermore, we revealed aberrant signaling in these cells.
Materials and methods

Cell culture and generation of SIRPα1-knockdown cells.
K562 cells were grown in RPMI (Gibco-BRL, Rockville, Md) containing 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. turer (Takara, Otsu, Japan), were employed for this study to obtain optimal effects. The target sequences of these siRNA expression vectors were, GAcAcAATGATATcAcAT and GccTcAAccGTTAcAGAGA. In addition, we employed the pcPURU6biSTOP vector (Takara) as a control. The electroporation procedure was performed as previously described (3, 4) . K562 clones stably transfected with the SIRPα1 siRNA vectors were isolated by limiting dilution by selection with 1 mg/ml puromycin for approximately 3-4 weeks. The clones were isolated and maintained for further analysis.
Microarray analysis. Total cellular RNA was isolated from parental and SIRPα1-knockdown cells using an RNA mini purification kit (Qiagen, Miami, FL) according to the manufacturer's protocol. The samples were then sent to the manufacturer and analyzed. A human 35K array (Operon Biotechnologies, Huntsville, AL) involving 35,000 human genes was employed for this study.
mRNA expression analysis. Total RNA was extracted from transgenic cells by the Isogen reagent (Nippon Gene, Tokyo, Japan) and reverse transcription was performed with Superscript II (Invitrogen). Quantitative real-time PCR was performed using the Quantitect SYBR-Green PCR reagent (Qiagen) according to the manufacturer's protocol and an Opticon mini real-time PcR instrument (Bio-Rad, Hercules, cA) as previously described (5) . The sequences of the primers were: β-catenin: forward, 5'-TGcAcATcAGGATAccc AGc-3' and reverse, 5'-GcAAGTTcAcAGAGGAcccc-3'; Aven: forward, 5'-GATTTcAGTGTccTccTTAG-3' and reverse, 5'-ccTTGccATcATcAGTTcTc-3' (3); interferoninducible transmembrane protein 1 (IFITM1): forward, 5'-TGcAcAAGGAGGAAcATGAG-3' and reverse, 5'-cTGT TAcAGAGccGAATAcc-3' (4); insulin-like growth factor (IGF)-1A: forward, 5'-GTGGATGcTcTTcAGTTcGTGT GTG-3' and reverse, 5'-TG GcATGTcAcTcTTcAcTcc-3' (5); glyceraldehyde-3-phosphate dehydrogenase (GAPdH): forward, 5'-GAAGGTGAAGGTcGGAGT-3' and reverse, 5'-GAAGATGGTGATGGGATTTc-3' (6). The thermal cycling conditions were: step 1, 95˚C for 15 min; step 2, 95˚C for 30 sec; step 3, 55˚C for 30 sec; step 4, 72˚C for 30 sec.
Steps 2-4 were repeated for 35 cycles. The copy number of each sample was calculated as previously described (7).
Surface marker expression analysis by flow cytometry. For flow cytometry analysis, the cells were incubated with PE-conjugated mouse anti-human cd172a (BioLegend, San diego, cA) or PE mouse IgG (BioLegend), lysed with FAcS lysis solution (Becton-dickinson, Mountain View, cA) and applied to a Beckman Coulter Epics XL flow cytometer (Beckman Coulter, Switzerland), as described previously (8, 9) .
Western blot analysis. First, the cells were collected and lysed in buffer A (10 mM Hepes, 10 mM Kcl, 1.5 mM Mgcl 2 , 1 mM Na 3 VO 4 , 0.5 mM dTT, 1X protease inhibitor cocktail) (Roche, Indianapolis, IN) for 10 min on ice. After 1,300 x g centrifugation for 10 min, the resulting supernatants were collected as cytosol extracts. The pellets were washed with buffer B (20 mM Hepes, 420 mM Nacl, 25% glycerol, 1.5 mM Mgcl 2 , 0.2 mM EdTA, 0.5 mM dTT, 1 mM Na 3 VO 4 , 1X protease inhibitor cocktail), suspended and incubated on ice for 10 min, centrifuged at 8,000 x g for 15 min and the supernatants were collected, representing the nuclear extract. Proteins of 20-30 µg were separated by SdS-PAGE, transferred to Hybond-P PVdF membranes (GE Healthcare, Piscataway, NJ) and immunoblotted as described previously (10) . To examine the expression of β-catenin, mouse monoclonal anti-β-catenin (Bd Biosciences, San Jose, cA) and rabbit polyclonal anti-RNA polymerase II (pol-II) (Santa cruz Biotechnology, Santa cruz, cA) antibodies were used. To examine the signaling, anti-phospho-ERK, anti-phospho-GSK-3β (Ser9) and anti-β-catenin rabbit polyclonal antibodies were purchased from cell Signaling Technology (Beverly, MA). Anti-total-ERK mouse monoclonal was obtained from Bd Biosciences.
Results
Establishment of SIRPα1-knockdown K562 cells. RNA interference using siRNAs has been widely explored for the suppression of cellular mRNA levels to investigate the functions of specific genes. In the present study, we used a plasmid vector-based siRNA expression system to silence SIRPα1 expression. We first generated human chronic myeloid leukemia K562 cells stably expressing SIRPα1 siRNAs as well as control siRNA vector-transfected clones as controls. K562 cells were selected for this study because of their relatively high transfection efficiency among hematopoietic cell lines. Among the >30 lines isolated and analyzed, clone 2-6 exhibited sufficient suppression of SIRPα1 mRNA and protein expressions ( Fig. 1 ). In addition, clone 1-2 had a modest level of SIRPα1 suppression compared with the vector-transfected clones vec 4, vec 5 and vec 6 ( Fig. 1) . Thereafter, clones 2-6 and 1-2 were used to assess the effects of SIRPα1 suppression, and were designated as K562SIRPα1-knockdown (K562SIRPα1Kd) cells.
Microarray analysis of SIRPα1-knockdown cells. To identify
SIRPα1 downstream target genes, microarray analysis were carried out in 2-6 cells and vec 6 cells (controls) using a human 35K array containing 35,000 human genes. The microarray analysis identified several candidate SIRPα1 target genes. Among the 35,000 genes examined, 155 genes were up-regulated by ≥2.5-fold in 2-6 cells compared with vec 6 cells. The top 100 up-regulated genes are shown in Table I . A further 21 genes were down-regulated in 2-6 cells by ≥2.5-fold compared with vec 6 cells (Table II) . These results suggest that a large portion of genes were up-regulated by SIRPα1 suppression. In this study, we focused on the genes with fully characterized functions that are known to play roles in hematopoiesis or oncogenesis, to clarify the roles of SIRPα1 in leukemogenesis. On this basis, we selected IGF-1A (5), IFITM1 (4), Aven (3) and β-catenin (11) , as candidates for SIRPα1 target genes for further analysis (Table I , bold type).
Induction of β-catenin by the suppression of SIRPα1 in K562 cells. Next, we evaluated the expression levels of these genes by quantitative real-time PcR. IGF-1A, IFITM1 and Aven expression in K562SIRPα1Kd cells (1-2, 2-6) was not higher than that in all of the control cell lines ( Fig. 2A and c ).
Among these candidate target genes analyzed, induction of β-catenin ( Fig. 2d ) in K562SIRPα1KD cells was significantly higher than that in all of the controls (vec 4, vec 5 and vec 6), suggesting that this gene is a candidate SIRPα1 target gene. Moreover, the protein expression was verified. As accumulation of nuclear β-catenin is a hallmark of the wnt/β-catenin pathway activation (12), we examined nuclear β-catenin expression. The expresion of nuclear β-catenin was significantly induced in K562SIRPα1Kd cells (Fig. 3) . These results further support the notion that β-catenin is a bona fide target of SIRPα1 suppression in K562 cells.
Down-regulation of SIRPa1 results in the constitutive phosphorylation of downstream signaling pathway components.
SIRPα1 is a negative regulator of signal transduction pathway in hematopoietic cells. Therefore, we investigated whether the reduction of SIRPα1 expression affected downstream signal transduction pathways in these cells. Therefore, we first examined the activation of ERK and Akt phosphorylation by western blotting. As shown in Fig. 4A , slight phosphorylation of ERK was reproducibly observed in K562SIRPα1Kd cells compared to their control, in two independent experiments. In addition, Fig. 4B demonstrates significant phosphorylation of Akt in K562SIRPα1Kd cells. Phosphorylation of Ser9 of GSK-3β, results in the inactivation of this protein, leading to the up-regulation of β-catenin (13) . Therefore, we next evaluated the phosphorylation status of GSK-3β. As we predicted, Ser9 of GSK-3β was phosphorylated in K562SIRPα1Kd cells (Fig. 4c) . collectively, the results illustrate that downregulation of SIRPα1 results in the aberrant phosphorylation of several signaling pathway components, such as ERK, Akt and GSK-3β. These may play a role in the induction of β-catenin in K562SIRPα1Kd cells.
Discussion
Qin et al have reported that overexpression of SIRPα1 by stably transfected SIRPα1 plasmid into the SK-Hep1 liver cancer cell line results in a decrease in the expression of β-catenin and cyclin d (14) . The authors concluded that SIRPα1 may block the cell cycle in liver cancer, inhibit cell proliferation and promote cell apoptosis by decreasing the expression of cyclin d1 and β-catenin. Although the mechanisms of the β-catenin suppression by the overexpression of SIRPα1 remain unsolved, their findings are quite consistent with our current study that SIRPα1 negatively regulates the expression of β-catenin. The Ras-ERK-mitogen-activated protein kinase (MAPK) pathway is frequently activated in hematological malignancies (15, 16) . In addition, phosphoinositide 3-kinase (PI3K)/Akt signaling is frequently activated in blasts of AML patients and strongly contributes to the proliferation, survival and drug resistance of these cells (17) . Although genetic alterations affecting the functions of transcription factors that regulate myeloid maturation play important roles in leukemogenesis (18, 19) , inappropriate MAPK, as well as PI3K activation may also play a role in leukemic transformation. Our current study revealed the contribution of the down-regulation of SIRPα1 to the constitutive activation of this aberrant signaling in leukemia cells. In addition, we examined the effect of specific signaling inhibitors (i.e. the MEK inhibitor, U0126 and the PI3K inhibitor, LY294002) on K562SIRPα1Kd cells and found that they do not apparently affect the expression of β-catenin, or the phosphorylation GSK-3β (data not shown). These results suggest that the induction of β-catenin induced by SIRPα1 suppression, does not occur through a single pathway, but is rather due to complex aberrant signaling. The bipartite transcription factor β-catenin/TcF has been recognized as the major effector of the wnt signaling pathway for more than a decade. It is known that activation of the wnt/β-catenin signaling pathway through loss-of-function mutations in the adenomatous polyposis coli (APc) protein and axin, or gain-of-function mutations in β-catenin are linked to various human cancers including colorectal carcinomas and melanomas (20) . However, until recently the role of β-catenin in normal and malignant hematopoiesis compared to that in solid tumors has not been evaluated extensively. Muller-Tidow et al were the first to identify a role of the wnt/β-catenin pathway in the pathogenesis of AML (21) . Activating mutations of the fms-like tyrosine kinase (FLT) 3, one of the commonest mutations in AML, was found to induce leukemogenic effects (22) . Subsequently, constitutive activation of the wnt/β-catenin signaling pathway has been documented in a significant portion of AML cases (11). Ysebaert et al reported that β-catenin was expressed in 61% of the 82 AML cases they examined (23) . In a survival analysis, they demonstrated that β-catenin appeared as a new independent prognostic factor predicting poor event-free survival and shortened overall survival (23) . A similar report was recently published by another group, in which analysis of a cohort of 59 AML patients, demonstrated that high expression of β-catenin is related to shortened overall survival (24) .
To our knowledge, this is a first report demonstrating the relationship between SIRPα1 and β-catenin in leukemia cells. As β-catenin expression is related to the adverse prognosis, our study may shed light on the importance of SIRPα1 expression, which is relatively easy to examine by flow cytometry, in predicting the prognosis of patients with hematological malignancies. 
